No Data
No Data
Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma
Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA
Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
Express News | Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting
Express News | Lyell Immunopharma Files Prospectus Related to Resale From Time to Time by Selling Stockholders of up to 37.5 Mln Shares of Common Stock - SEC Filing
Teddy123 OP : Move won't u